Kodiak Sciences (KOD) vs Tarsus Pharmaceuticals (TARS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kodiak Sciences (KOD) has outperformed Tarsus Pharmaceuticals (TARS) over the past year, gaining 540.1% versus a gain of 7.6%. Over five years, TARS leads with a +158.1% price change compared with -18.7% for KOD. Kodiak Sciences is the larger company by market cap ($5.87 billion vs $3.42 billion), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KOD | TARS |
|---|---|---|
| Share price | $93.36 | $73.07 |
| Market cap | $5.87B | $3.42B |
| 1-day change | +2.50% | -0.73% |
| YTD return | +225.75% | -10.10% |
| 1-year return | +540.06% | +7.59% |
| 5-year return | -18.66% | +158.10% |
| EPS (TTM) | $-4.19 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $451.36M |
| Revenue growth (YoY) | — | +146.71% |
| Net income (latest FY) | $-229.97M | $-66.42M |
| Operating margin | — | -15.72% |
| Net margin | — | -14.72% |
| 52-week high | $104.00 | $91.53 |
| 52-week low | $10.94 | $53.89 |
| Distance from 52-week high | -10.23% | -20.17% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +24.97% | +36.17% |
| Average volume | 1.56M | 894.35K |
| Shares outstanding | 62.85M | 46.79M |
| Employees | 141 | 370 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KOD has outperformed TARS by 532.5 percentage points over the past year.
About Kodiak Sciences
KOD stock →Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
KOD vs TARS FAQ
Which is bigger, Kodiak Sciences or Tarsus Pharmaceuticals?
Kodiak Sciences (KOD) is larger, with a market capitalization of $5.87B compared with $3.42B for Tarsus Pharmaceuticals (TARS).
Which stock has performed better over the past year, KOD or TARS?
KOD returned +540.06% over the past 12 months, compared with +7.59% for TARS (price return, excluding dividends). Past performance does not predict future results.
Are Kodiak Sciences and Tarsus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.